Data as of Mar 07
| +0.04 / +0.58%|
Biota Pharmaceuticals, Inc. is an anti-infective drug development company, which focuses on respiratory diseases, mainly influenza. The company develops various products, which include Zanamivir, Inavir, Phoslyra, and BioStar OIA FLU and BioStar OIA FLU A/B. The Zanamivir, which is marketed under the name Relenza, is an antiviral drug for the treatment and prevention of influenza. The Inavir is long acting neuraminidase inhibitor which is also for treatment and prevention of influenza. The Phoslyra reduce serum phosphorus in patients with end stage renal disease, and BioStar OIA FLU and BioStar OIA FLU A/B used for rapid influenza diagnostic test. Biota Pharmaceuticals was founded on November 9, 2012 and is headquartered in Rockville, MD.
|Russell H. Plumb||President, Chief Executive Officer & Director|
|Damian T. Lismore||Chief Financial Officer & Head-Investor Relations|
|Joseph M. Patti||EVP-Corporate Development & Strategy|
|Leigh Farrell||Vice President-Business Development|
|John Nicholas Lambert||Vice President-Product Development Operations|